Effects of selegiline, phenylpropanolamine, or a combination of both on physiologic and behavioral variables in healthy dogs.
OBJECTIVE
To determine effects of selegiline hydrochloride, phenylpropanolamine (PPA), or a combination of both on physiologic and behavioral variables in dogs.


METHODS
40 adult hound-type dogs.


METHODS
Dogs were assigned to 4 groups. One group received selegiline (1 mg/kg, PO, q 24 h) and PPA (1.1 mg/kg, PO, q 8 h), a second group received selegiline alone, a third group received PPA alone, and a fourth group received neither drug. Dogs were observed 3 times/d throughout the 30-day study (daily during the first week, on alternate days during the next 2 weeks, and again daily during the final week). Observers recorded rectal temperature, pulse, respiratory rate, oscillometric blood pressure, and lead-II ECG and assessed 4 behaviors, using an analogue scale. Variables were compared among treatment groups by use of a 2-factor ANOVA with data categorized into three 10-day treatment periods. A similar comparison was made among treatment groups with data categorized by time of observation (morning, afternoon, or evening) for all study days.


RESULTS
Variables did not differ among groups at study initiation. Pulse rate was the only variable that differed significantly among treatment groups during the study. During the first 10 days of treatment, dogs receiving PPA had a lower pulse rate than dogs that did not. Although signs of illness were apparent in a few dogs, illness did not appear to be related to treatment.


CONCLUSIONS
Adverse effects were not detected after administration of selegiline, PPA, or a combination of the drugs in healthy dogs.
Cohn
Leah A
LA
Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia 65211, USA.
Dodam
John R
JR
Szladovits
Balazs
B
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D004285:Dogs / Q000378:metabolism / Q000502:physiology* / Q000523:psychology; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000187:drug effects / Q000662:veterinary; D005260:Female; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010665:Phenylpropanolamine / Q000494:pharmacology*; D011674:Pulse / Q000662:veterinary; D011897:Random Allocation; D012119:Respiration / Q000187:drug effects; D012642:Selegiline / Q000494:pharmacology*; D013566:Sympathomimetics / Q000494:pharmacology*
D008996:Monoamine Oxidase Inhibitors; D013566:Sympathomimetics; D012642:Selegiline; D010665:Phenylpropanolamine